

Advancing Oxidative Stress Technology



OXIS

OXIS INTERNATIONAL, INC.

Rodman and Renshaw, LLC
Global Investment Conference

London, UK // May 16–18, 2010

SAFE HARBOR STATEMENT



OXIS Advancing Oxidative
Stress Technology

Except for the historical information contained herein, the matters discussed in this presentation include forward looking statements. Such statements in this presentation, including future financings necessary for operations or acquisitions and future product launch dates are only predictions and reflect current beliefs and expectations of the Company. Actual results may differ materially from those predicted in such forward looking statements due to the risks and uncertainties inherent in the Company's business, including, without limitation, risk and uncertainties in the obtaining possibly required regulatory approvals, market acceptance of and continuing demand for the Company's products, the impact of competitive products and pricing and the Company's ability to obtain additional financing to support its operations. We refer you to the risks and factors detailed from time to time in the Company's Annual Reports on Form 10-K and its Quarterly Reports on Form 10-Q. The Company undertakes no obligation to revise or update this presentation to reflect circumstances after the date hereof.

Then and Now



oxis



- Pink Sheet Company
 - Equity marketcap 3/31/09 = \$1.9 Million
 - 60,000 average daily trading volume (US and Europe)
- No cash, many cash liabilities
- Limited management and Corporate Board, no functioning science committee
- Unable to meet SEC filing requirements
- No developed products
- No complete strategic plan

OXIS RECENT MILESTONE ACHIEVEMENTS



OXIS Advancing Oxidative Stress Technology

- Management
 - Anthony Cataldo appointed Chairman & CEO
 - Bernie Landes appointed President
 - New CFO & Corporate Secretary
 - Additional members with strong experience in marketing and distribution being recruited
- Board of Directors - Revitalized with new members and functioning committees
- Scientific Advisory Board Created (With world class recognized experts)
- Stock Trading
 - Equity market cap 3/31/10= \$13.7 Million
 - Oxis.OB, OXI.PA
 - Average daily trading volume over 1,500,000 shares per day (US and Europe)
- Financial Status
 - \$2 million capital raised in October 2009
 - Current liabilities and ongoing expenses at manageable levels
- Products
 - Two nutraceutical products set to launch in summer 2010 (Many more in pipeline)
 - Re-certifying FDA approved drug for veterinary medicine
- SEC Filings – Up-to-date and complete



- Focusing on research, development and sale of products to combat oxidative stress – common abnormality in which free radicals overwhelm antioxidant and other bodily defenses and likely contribute to disease and aging
- Building on an estimated \$75 million previously invested in IP development
- Developing multiple natural substance based products for substantial markets:
 - Nutraceuticals
 - Personal Care (including Cosmeceuticals)
 - Animal Health (drugs and supplements)
 - Therapeutic Compounds
- Emphasizing L-Ergothioneine (“ERGO”), a highly potent, patent protected, multifaceted antioxidant
- Leveraging multiple intellectual property holdings including: 12 patents and 7 patents pending in oxidative stress technologies – continue to build IP with help of SAB
- Anticipating growth internally, through mergers and acquisitions, and in/out-licensing

OXIS ADDRESSES TWO MAJOR HEALTH ISSUES: OXIDATIVE STRESS AND INFLAMMATION



OXIS Advancing Oxidative
Stress Technology

- Heart health (Inflammation in arteries)
- Brain health (Decline in cognitive ability, Alzheimer's)
- Resistance against diseases (Maintain physiological homeostasis)
- Anti-aging/skin care (e.g., Skin protection/rejuvenation)
- Inflammation (Arthritis, joint pain)
- Detoxification (Liver)
- Blood sugar regulation (Protection against developing diabetes)

...WITH VERY LARGE MARKETS

OXIS CONSUMER PRODUCTS*

- Dietary supplements: \$25 billion
- Functional foods and beverages: \$37 billion
- Personal care (including cosmetics): \$10 billion
- Companion animal supplements: \$17 billion


OXIS THERAPEUTIC/CLINICAL PRODUCTS

- Veterinary health: \$11 billion**
- Pharmaceutical compounds for target indications – several exceeding \$100 million in size

*=Market size estimates for 2008 by Nutritional Business Journal

**=Market size estimate for 2008 by Vetnosis, Ltd.

Scientific Background



oxis


OXIDATIVE STRESS: CREATED WHEN FREE RADICALS EXCEED BODY'S NATURAL DEFENSES



Advancing Oxidative
Stress Technology

FREE RADICALS


- An atom or group of atoms with unpaired electrons, creating unstable situations where cells and important organs may be damaged
- Generated normally as result of naturally occurring processes when the body's cells use oxygen to produce energy
- Also result from other sources: air pollution, tobacco smoke, ultraviolet rays, agricultural chemicals, psychological stress, exhaustive exercise, drug intake and inflammation
- Increases with aging and disease



FREE RADICALS CAN CAUSE A VARIETY OF DESTRUCTIVE ACTIONS ON CELLS






Advancing Oxidative Stress Technology





- Created by an imbalance in the physiologic ability (natural and ingested antioxidants) to combat free radicals
- May be accelerated by excess alcohol and certain foods, certain pharmaceutical drugs, strenuous exercise, inflammation and aging process





- Internally produced antioxidant enzymes
 - Superoxide dismutase (SOD)
 - Catalase
 - Glutathione Peroxidase (GPx)
- Ingested in diet and supplements:
 - Vitamin A, C, E, beta-carotenes
 - Proanthocyanins, anthocyanins, polyphenols, flavonoids, and metal chelators
- However, natural antioxidant systems can be overwhelmed creating Oxidative Stress leading to disease states and premature aging

ERGO (ERGO): PROPRIETARY SCIENCE BASE FOR INITIAL PRODUCTS




OXIS Advancing Oxidative
Stress Technology

- Highly potent naturally occurring multifaceted antioxidant - can't be made internally by humans
 - Humans have special transporter system to concentrate ERGO in specific locations as needed
 - Found naturally in certain mushrooms, grapes, other foods, but not in quantities that can be ingested in sufficient amounts to help humans
 - OXIS has proprietary technology to make ERGO in sufficient strength to be a dietary supplement and food/beverage ingredient
 - Oxis has 3 patents and 2 patent pending applications for ERGO (Several more in development)
- Significant well-documented benefits of ERGO (based on over 100 research papers and studies):
 - Conserves other antioxidants- Vitamin E and Glutathione (GSH)
 - Increases respiration and oxidation of fat
 - Reduces damage from ultraviolet radiation
 - Protects mitochondria from damage
 - Directly scavenges certain free radicals and oxidants
 - Protects against damage from neuro-toxins that maybe responsible for creating cognitive decline
 - Protects red blood cells


ERGO: A MULTI-FACETED, ANTI-INFLAMMATORY ANTIOXIDANT



OXIS Advancing Oxidative Stress Technology



Consumer Products



oxis

NUTRITION AND WELLNESS

- Dietary Supplements
- Functional Foods
- Functional Beverages (e.g., energy drinks)

PERSONAL CARE

- Creams
- Cosmetics
- Hair care

- Build direct to consumer sales relationships to maximize margins and repeat sales
- Create marketing alliances with key thought leaders by product category
- Establish multiple channels:
 - Multi-level marketing
 - Internet sales
 - TV Infomercials
 - Long and short form radio infomercials
 - Direct mail
 - Traditional retail approaches
- Two product launches for Summer 2010 (Others to follow shortly afterwards)
 - “Ergo-Pure” - ERGO in pure form as a highly potent multifaceted antioxidant
 - “Ergo-Plex” – ERGO plus other functional nutraceutical ingredients directed at Joint Health/Pain relief.
- Actively exploring several joint venture and acquisition opportunities


GO TO MARKET STRATEGIES – PERSONAL CARE PRODUCTS



OXIS Advancing Oxidative
Stress Technology

- Develop line of ERGO based products with mass marketer (Walmart, Walgreens, CVS, etc.)
- Develop line of products independently – go to market via direct mail, Internet, infomercials or combination
- Develop strategic partnership with spa market participants and promote custom developed products
- Develop separate line of personal care products for dermatology market and then also sell at upscale retail channels such as Bloomingdales and Sephora

Therapeutic and Clinical Products



oxis

THERAPEUTIC AND CLINICAL PRODUCTS – HIGH UPSIDE POTENTIAL



- Oxis has 9 patents and 5 patent pending applications that cover a number of current and potential therapeutic and clinical applications
- Most indications for still available for out-licensing to biotech and pharmaceutical companies
- Anti-inflammatory indications seem most promising
- Several ERGO analogs (antioxidant mimics and variations of ERGO) also may have promise in neurodegenerative (Alzheimer's and Parkinson's), diabetes and cardiovascular diseases

GAME PLAN:

- Initiate out-license program
- Add to IP based on relationships with leading researchers as guided by SAB
- JVs with third parties (Several under consideration)



BXT-51072

- **Action:** Low weight anti-inflammatory glutathione peroxidase mimicking molecule that metabolizes lipid peroxides
- **Target Indications:** cardiovascular and inflammatory bowel diseases

LIPID SOLUBLE ANTIOXIDANT COMPOUNDS

- **Action:** Natural cell penetrating potent (20-40X) agent that mimics Vitamin E
- **Target Indications:** neurodegenerative (Alzheimer's and Parkinson's) and cardiovascular diseases

SUPEROXIDE DISMUTASE (“SOD”) RELATED COMPOUNDS

- **Action:** Naturally occurring ubiquitous enzyme that reduces superoxide (a pivotal free radical) found in all living organisms
- **Target Indications:** Inflammatory joint disease and prevention of radiation toxicity

THERAPEUTIC AND CLINICAL PRODUCTS – FDA APPROVED DRUG FOR ANIMALS



OXIS Advancing Oxidative
Stress Technology

- Palosein™ - anti-inflammatory form of SOD (Orgotein)
- Derived from bovine liver
- Previously sold by Oxis
- Currently re-certifying manufacturing process to resume sales
- In discussions with potential distribution partners

Management and Scientific Advisory Board



oxis

MANAGEMENT TEAM



OXIS Advancing Oxidative Stress Technology

ANTHONY CATALDO
CHAIRMAN & CEO,
DIRECTOR

- Overall management, financings, investor and public relations
- Multiple times public company CEO or Chairman with life science focus (Calypte, Senetek)
- Significant public company investor relations and financing experience

BERNIE LANDES
PRESIDENT

- Overall product/market strategy, mergers, acquisitions, alliances nutraceutical and cosmeceutical product development and management
- Multiple top management and advisory roles in nutrition, natural foods, supplements, skin care
- Experience at Suracell, Monavie, Zila, Paracelsian, Alacer, Health Valley

MICHAEL HANDELMAN
CFO & TREASURER

- Overall responsibility for financial management and reporting
- Multiple times CFO including LA Kings Hockey Team and several start-ups
- CPA

GARY POST
SECRETARY &
DIRECTOR

- Corporate Governance, Administration, Special Projects
- Multiple interim public and private company Board Member/CEO/COO – initiated Oxis strategy transition
- Investing and advising with Ambient Advisors, McKinsey, Kidder Peabody, Drexel Burnham

A STRONG SAB IS ACTIVELY ASSISTING WITH KEY CONTRIBUTIONS:

- Participating in product development
- Evaluating and contributing to additional IP opportunities
- Evaluating merger, in and out-license opportunities
- Assisting in communicating the Oxis science story to investors



OKEZIE I. AROUMA, BSc, MBA, PhD, MSc, DSc


- Professor of Pharmaceutical and Biomedical Sciences, Touro College of Pharmacy, NYC
- Biochemist, world expert and leading researcher re: Ergothioneine and Oxidative Stress
- Author of 10 books and 250 peer review papers focused on oxidative stress, dietary antioxidants and diseases of overt inflammation, two patent applications

JOHN E. REPINE, M.D.

- Waring Professor of Medicine, Pediatrics and Surgery at University of Colorado and Director of Webb-Waring Center
- Pulmonary/Critical Care Specialist and expert in antioxidant and inflammatory research
- Author of over 300 peer review articles and 14 patent applications

Other candidates under consideration for the SAB have complementary specialties in science and product development

Summary



oxis

MARKET SNAPSHOT (April 30, 2010)



OXIS Advancing Oxidative
Stress Technology

COMMON STOCK TICKER:

(OXIS.OB) (OXI.PA)

STOCK PRICE:

\$0.19

52 WEEK RANGE:

\$0.04 – \$0.61

SHARES OUTSTANDING:

102.5 million

MARKET CAPITALIZATION:

\$ 19.5 million

KEY POINTS



- Large potential markets for unique products, especially incorporating ERGO
- Strong IP position
- Diversified strategies for growth
- Highly qualified Management and SAB team

Thank You



oxis